Cedars-Sinai Medical Center, Division of Medical Oncology, Department of Medicine, Los Angeles, CA 90048, USA.
Takeda Development Center Americas, Inc., 95 Hayden Avenue, Lexington, MA 02421, USA.
Future Oncol. 2022 Jun;18(20):2499-2510. doi: 10.2217/fon-2022-0194. Epub 2022 May 24.
To conduct an indirect treatment comparison (ITC) of the relative efficacy of brigatinib and alectinib for progression-free survival in people with tyrosine kinase inhibitor (TKI)-naive -positive non-small-cell lung cancer (NSCLC). Final aggregate and patient-level data from the ALTA-1L trial comparing brigatinib to crizotinib and published aggregate data from ALEX (comparing alectinib to crizotinib) were contrasted using Bucher ITC and matching-adjusted indirect comparisons (MAICs). No statistically significant differences were identified between brigatinib and alectinib in reducing the risk of disease progression overall and in patients with baseline central nervous system metastases. Brigatinib appeared similar to alectinib in reducing risk of disease progression for people with TKI-naive -positive NSCLC.
对brigatinib 和 alectinib 用于未经酪氨酸激酶抑制剂（TKI）治疗的阳性非小细胞肺癌（NSCLC）患者的无进展生存期的相对疗效进行间接治疗比较（ITC）。使用 Bucher ITC 和匹配调整间接比较（MAIC）对比来自比较 brigatinib 与克唑替尼的 ALTA-1L 试验的最终综合和患者水平数据以及来自比较 alectinib 与克唑替尼的 ALEX 的已发表综合数据。在总体和基线中枢神经系统转移患者中，brigatinib 和 alectinib 降低疾病进展风险方面没有统计学上的显著差异。对于未经 TKI 治疗的阳性 NSCLC 患者，brigatinib 在降低疾病进展风险方面似乎与 alectinib 相似。
